MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 135 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.42 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $75,649 | -49.5% | 518 | -20.2% | 0.01% | -42.1% |
| Q2 2023 | $149,919 | -62.0% | 649 | -60.2% | 0.02% | -64.8% |
| Q1 2023 | $394,642 | -29.5% | 1,629 | -15.6% | 0.05% | -32.5% |
| Q4 2022 | $559,892 | +347.9% | 1,929 | 0.0% | 0.08% | +281.0% |
| Q3 2022 | $125,000 | -26.5% | 1,929 | +10.5% | 0.02% | -27.6% |
| Q2 2022 | $170,000 | -9.6% | 1,746 | -8.9% | 0.03% | 0.0% |
| Q1 2022 | $188,000 | -6.0% | 1,917 | -18.7% | 0.03% | -3.3% |
| Q4 2021 | $200,000 | +46.0% | 2,358 | +37.2% | 0.03% | +30.4% |
| Q3 2021 | $137,000 | -19.4% | 1,719 | -1.5% | 0.02% | -20.7% |
| Q2 2021 | $170,000 | +7.6% | 1,746 | +29.1% | 0.03% | +3.6% |
| Q1 2021 | $158,000 | +113.5% | 1,352 | +102.7% | 0.03% | +100.0% |
| Q4 2020 | $74,000 | +42.3% | 667 | +53.3% | 0.01% | +27.3% |
| Q3 2020 | $52,000 | +100.0% | 435 | +90.0% | 0.01% | +83.3% |
| Q2 2020 | $26,000 | – | 229 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HealthCor Management, L.P. | 902,601 | $100,342,000 | 3.87% |
| L1 Capital Pty Ltd | 113,464 | $12,608,000 | 2.35% |
| Avoro Capital Advisors LLC | 1,225,000 | $136,183,000 | 2.34% |
| Tao Capital Management LP | 51,396 | $5,714,000 | 1.40% |
| ARMISTICE CAPITAL, LLC | 316,000 | $35,130,000 | 1.20% |
| ACUTA CAPITAL PARTNERS, LLC | 32,500 | $3,613,000 | 0.98% |
| Capital Impact Advisors, LLC | 24,351 | $2,707,000 | 0.66% |
| Baker Brothers Advisors | 1,499,213 | $166,668,000 | 0.63% |
| Rock Springs Capital Management LP | 256,768 | $28,545,000 | 0.60% |
| SHIKIAR ASSET MANAGEMENT INC | 12,000 | $1,334,000 | 0.48% |